Darunavir outcomes study: Comparative effectiveness of virologic suppression, regimen durability, and discontinuation reasons for three-class experienced patients at 48 weeks

AIDS Research and Human Retroviruses

Volumn 26, Issue 12, 2010, Pages 1279-1285

  Willig, James H ^a   Aban, Inmaculada ^b   Nevin, Christa R ^a   Ye, Jiatao ^b   Raper, James L ^a   McKinnel, James A ^a   Delaitsch, Lori L ^c   Mrus, Joseph M ^c   De La Rosa, Guy R ^c   Mugavero, Michael J ^a   Saag, Michael S ^a  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c Tibotec Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; DARUNAVIR; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR PLUS RITONAVIR; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NELFINAVIR; PROTON PUMP INHIBITOR; RALTEGRAVIR; RITONAVIR;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; NONHUMAN; OBSERVATIONAL STUDY; PATIENT CODING; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; SURVIVAL; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PROSPECTIVE STUDIES; SULFONAMIDES; TREATMENT OUTCOME;

EID: 78650272914     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2010.0059     Document Type: Article

References (23)

1. McKinnell JA, Lin HY, Nevin CN, et al. Early virologic suppression with three-class experienced patients: 24-week effectiveness in the darunavir outcomes study. AIDS 2009;23:1539-1546.
2. Arasteh K, Yeni P, Pozniak A, et al. Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96. Antivir Ther 2009;14:859-864.
3. Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: A pooled subgroup analysis of data from two randomised trials. Lancet 2007;369:1169-1178.
4. Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for pre-viously treated patients with R5 HIV-1 infection. N Engl J Med 2008;359:1429-1441.
5. Hammer SM, Eron JJ, Jr., Reiss P, et al. Antiretroviral treat-ment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008;300:555-570.
6. Imaz A, Del Saz SV, Ribas MA, et al. Raltegravir, etravirine, and ritonavir-boosted darunavir: A safe and successful res-cue regimen for multidrug-resistant HIV-1 infection. J Acquir Immune Defic Syndr 2009;52:382-386.
7. Katlama C, Esposito R, Gatell JM, et al. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS 2007;21:395-402.
8. Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled tri-als. AIDS 2009;23:2289-2300.
9. Lazzarin A, CampbellT, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a rando-mised, double-blind, placebo-controlled trial. Lancet 2007;370:39-48.
10. Madruga JV, Berger D, McMurchie M, et al. Efficacy and safety of darunavir-ritonavir compared with that of lopina-vir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: A randomised controlled phase III trial. Lancet 2007;370:49-58.
11. Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a rando-mised, double-blind, placebo-controlled trial. Lancet 2007; 370:29-38.
12. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008;359:339-354.
13. Routman JS, Willig JH, Westfall AO, et al. Comparative ef-ficacy versus effectiveness of initial antiretroviral therapy in clinical trials versus routine care. Clin Infect Dis 2010;50:574-584.
14. Chen RY, Westfall AO, Mugavero MJ, et al. Duration of highly active antiretroviral therapy regimens. Clin Infect Dis 2003;37:714-722.
15. Willig JH, Echevarria J, Westfall AO, et al. Durability of initial antiretroviral therapy in a resource constrained setting and the potential need for zidovudine weight-based dosing. J Acquir Immune Defic Syndr 2010;53:215-221.
16. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008;11:44-47.
17. Willig JH, Abroms S, Westfall AO, et al. Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy. AIDS 2008;22:1951-1960.
18. Gatanaga H, Tsukada K, Honda H, et al. Detection of HIV type 1 load by the Roche Cobas TaqMan assay in patients with viral loads previously undetectable by the Roche Cobas Amplicor Monitor. Clin Infect Dis 2009;48:260-262.
19. Lima V, Harrigan R, and Montaner JS. Increased reporting of detectable plasma HIV-1 RNA levels at the critical threshold of 50 copies per milliliter with the Taqman assay in com-parison to the Amplicor assay. J Acquir Immune Defic Syndr 2009;5:3-6.
20. Smit E, Bhattacharya S, Osman H, and Taylor S. Increased frequency of HIV-1 viral load blip rate observed after switching from Roche Cobas Amplicor to Cobas Taqman assay. J Acquir Immune Defic Syndr 2009;51:364-365.
21. Willig JH, Nevin CR, Willig AL, et al. Cost ramifications of increased reporting of detectable plasma HIV-1 RNA levels by the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 version 1.0 viral load test. J Acquir Immune Defic Syndr 2010;54:442-444.
22. Yazdanpanah Y, Fagard C, Descamps D, et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: Results of the ANRS 139 TRIO trial. Clin Infect Dis 2009;49:1441-1449.
23. Cramer JA, Benedict A, Muszbek N, Keskinaslan A, and Khan ZM. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: A review. Int J Clin Pract 2008;62:76-87.